#1 Clinical Trials Search in Europe

Human Igg1 Kappa Monoclonal Antibody Against Crlf2

This article discusses ongoing clinical trials investigating the use of Verekitug (UPB-101), a human IgG1 kappa monoclonal antibody against CRLF2, for treating severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). These Phase 2 studies aim to evaluate the efficacy and safety of Verekitug in adult patients with these respiratory conditions. The trials are designed to assess various aspects of the drug’s performance, including its effects on disease symptoms, lung function, and overall patient well-being.

Table of Contents

What is Verekitug (UPB-101)?

Verekitug, also known as UPB-101, is a new medication being developed to treat severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). It is classified as a human IgG1 kappa monoclonal antibody that targets a specific protein in the body called CRLF2[1][2].

How Does It Work?

Verekitug works by targeting and blocking the CRLF2 protein, which is believed to play a role in the inflammatory processes involved in asthma and CRSwNP. By inhibiting this protein, Verekitug may help reduce inflammation in the airways and nasal passages, potentially improving symptoms for patients with these conditions[1][2].

What Conditions Does Verekitug Treat?

Verekitug is being studied for the treatment of two main conditions:

  1. Severe Asthma: A chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to breathing difficulties[1].
  2. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A condition where the sinuses are inflamed for an extended period, and soft, painless growths called nasal polyps develop in the nasal passages and sinuses[2].

Current Clinical Trials

Verekitug is currently being evaluated in two Phase 2 clinical trials:

  1. VALIANT Study: This trial is assessing the efficacy and safety of Verekitug in adults with severe asthma. The study aims to determine if Verekitug can reduce asthma exacerbations, improve lung function, and enhance overall asthma control[1].
  2. VIBRANT Study: This trial is investigating the effectiveness and safety of Verekitug in patients with chronic rhinosinusitis with nasal polyps. The study is evaluating whether Verekitug can reduce nasal polyp size, improve nasal congestion, and decrease the need for surgery or systemic corticosteroids[2].

How is Verekitug Administered?

Verekitug is administered as a subcutaneous injection. This means it is injected just under the skin. In the clinical trials, different dosing regimens are being tested:

  • For severe asthma: Doses of 100 mg every 12 weeks, 400 mg every 24 weeks, or 100 mg every 24 weeks are being evaluated[1].
  • For CRSwNP: A dose every 12 weeks for 24 weeks is being studied[2].

Potential Benefits

If proven effective, Verekitug could offer several potential benefits for patients:

  • Reduction in asthma exacerbations (sudden worsening of asthma symptoms)[1]
  • Improvement in lung function[1]
  • Better control of asthma symptoms[1]
  • Reduction in nasal polyp size[2]
  • Improvement in nasal congestion and other symptoms of CRSwNP[2]
  • Decreased need for systemic corticosteroids or surgery for nasal polyps[2]

Possible Side Effects

As Verekitug is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring participants for any adverse events. Common side effects of similar biologic medications may include injection site reactions, headache, and upper respiratory tract infections. However, it’s important to note that individual experiences may vary, and more information will be available as the clinical trials progress[1][2].

Conclusion

Verekitug (UPB-101) represents a promising new approach to treating severe asthma and chronic rhinosinusitis with nasal polyps. By targeting the CRLF2 protein, it may offer a novel way to manage these challenging conditions. However, it’s important to remember that Verekitug is still in the investigational stage. More research is needed to fully understand its efficacy and safety profile. Patients with severe asthma or CRSwNP should continue to work closely with their healthcare providers to manage their conditions and discuss potential new treatment options as they become available.

Aspect Asthma Trial CRSwNP Trial
Study Phase Phase 2 Phase 2
Design Randomized, Double-blind, Placebo-controlled, Multi-center Randomized, Double-blind, Placebo-controlled, Multi-center
Primary Endpoint Annualized Asthma Exacerbation Rate (AAER) over 60 weeks Change from Baseline at Week 24 in Nasal Polyp Score (NPS)
Key Secondary Endpoints Change in pre-BD FEV1, FeNO, ACQ-6 Change in Nasal Congestion Score, sinus opacification, need for systemic corticosteroids or surgery
Dosing Regimens 100 mg Q12W, 400 mg Q24W, 100 mg Q24W, or placebo Verekitug Q12W for 24 weeks or placebo
Treatment Duration 60 weeks 24 weeks
Key Inclusion Criteria Severe asthma, history of exacerbations, ACQ-6 score ≥ 1.5 CRSwNP diagnosis, history of exacerbations or surgery, stable background therapy

FAQ

  • What is Verekitug (UPB-101)? Verekitug (UPB-101) is a human IgG1 kappa monoclonal antibody that targets CRLF2, a protein involved in inflammatory processes. It is being studied as a potential treatment for severe asthma and chronic rhinosinusitis with nasal polyps.
  • What are the main objectives of the clinical trials for Verekitug? The main objectives are to assess the efficacy and safety of Verekitug compared to placebo. For asthma, the trials aim to evaluate its effect on asthma exacerbations, lung function, and airway inflammation. For CRSwNP, the focus is on reducing nasal polyp size, improving nasal congestion, and assessing changes in sinus opacification.
  • How is Verekitug administered in these trials? Verekitug is administered as a subcutaneous injection. In the asthma trial, different dosing regimens are being tested, including 100 mg every 12 weeks, 400 mg every 24 weeks, and 100 mg every 24 weeks. In the CRSwNP trial, it is given every 12 weeks for 24 weeks.
  • Who is eligible to participate in these clinical trials? Eligible participants are adults aged 18-75 with a diagnosis of either severe asthma or chronic rhinosinusitis with nasal polyps. Specific criteria include a history of asthma exacerbations or nasal polyp symptoms, and stable use of background medications. Participants must meet additional health and medical history requirements.
  • What are the primary endpoints of these clinical trials? For the asthma trial, the primary endpoint is the annualized asthma exacerbation rate over 60 weeks of treatment. For the CRSwNP trial, the primary endpoint is the change from baseline in nasal polyp score at week 24. Both trials also include various secondary endpoints to assess different aspects of disease improvement and drug safety.

Ongoing Clinical Trials on Human Igg1 Kappa Monoclonal Antibody Against Crlf2

  • Study of Verekitug to improve symptoms in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Hungary Ireland Latvia +5

  • Long-term safety and effectiveness study of verekitug injections in adults with severe asthma who completed the VALIANT trial

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Italy Poland Spain

  • Study on the Effects of Verekitug (UPB-101) for Patients with Chronic Rhinosinusitis with Nasal Polyps Using Nasal Corticosteroids

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Poland Spain

  • Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Italy Poland Spain

Glossary

  • CRLF2: Cytokine Receptor-Like Factor 2, a protein involved in inflammatory processes that is targeted by Verekitug.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. It is used to detect or measure the amount of a specific substance in the body or to treat diseases.
  • Subcutaneous injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Asthma exacerbation: A worsening of asthma symptoms that may require additional treatment or hospitalization.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • FeNO: Fractional exhaled Nitric Oxide, a biomarker of airway inflammation used in asthma management.
  • ACQ-6: Asthma Control Questionnaire-6, a tool used to assess asthma control in patients.
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A condition characterized by inflammation of the nose and sinuses with the presence of nasal polyps, which are soft, painless, noncancerous growths.
  • Nasal Polyp Score (NPS): A measure used to assess the size and extent of nasal polyps through endoscopic examination.
  • Lund-Mackay (LMK) score: A system used to evaluate the extent of sinus opacification on CT scans in patients with chronic rhinosinusitis.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-verekitug-upb-101-for-adults-with-severe-asthma/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-verekitug-upb-101-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps-using-nasal-corticosteroids/